DHF, DMR, DHR, and EU Technical Documentation Structure for Inspections, Audits, and Submissions
Introduction:
Design history, manufacturing records, and production evidence are where most medical device compliance cracks actually begin. not during inspections, but years earlier in documentation decisions. This article cuts through theory and guidance language to explain how DHF, DMR, and DHR truly work together across the full device lifecycle. Drawing on decades of field-tested regulatory experience, it shows how to structure these records in a way regulators recognize, auditors respect, and quality teams can realistically maintain. If you’ve ever struggled with change control, software updates, or EU technical documentation alignment, this is the clarity you’ve been missing.
Introduction:
Design history, manufacturing records, and production evidence are where most medical device compliance cracks actually begin. not during inspections, but years earlier in documentation decisions. This article cuts through theory and guidance language to explain how DHF, DMR, and DHR truly work together across the full device lifecycle. Drawing on decades of field-tested regulatory experience, it shows how to structure these records in a way regulators recognize, auditors respect, and quality teams can realistically maintain. If you’ve ever struggled with change control, software updates, or EU technical documentation alignment, this is the clarity you’ve been missing.
Caveat. There are many ways to meet the requirements of the Design History File (820.30), or the Design and Development File (ISO 13485, 7.3); the Device Master Record (DMR, the device “recipe”, 820.181); and the Device History Record (DHR, the device’s lot record, 820.184), required by the Device cGMPs as well as comparable documentation and Technical Documentation required by the EU and other countries other than the USA . The following is one field tested approach, vetted over many years by various regulatory agencies and Notified Bodies (in inspections / audits, submissions, responses / remediations).
This brief discussion covers the general basic device documentation for regulatory, quality assurance and production requirements worldwide.
In addition to starting a new DHF for a new device, a requirement, many companies start a new DHF for major changes to their existing devices. If minor changes they handle under the CGMPs (Change Control, 820.40(b)). Moderate changes and similar could also be handled by an addendum to the existing DHF. Of course the DHF can be open for the life of the device (which I view as a change control nightmare); I recommend the DHF be closed at Design Transfer, when all final versions of documentation are approved and sent to their appropriate areas in the company, ready for device production.
As with most of the points discussed herein, there are more than one correct approach.
Generally I recommend to my clients if they ask, that the DHF be used for newly developed devices or major changes to an existing device (with each new major change an addendum to the original DHF, or a new, cross-referenced DHF), which require some type of control of a series of development changes per 820.30.
For a minor / simple change, I recommend change control under the CGMPs (820.40(b)), which at most companies is under a Change Request / Change Order (the CR when approved, can become the CO). To it are attached the verification / test information / references, e.g., test report number / Lab Book Project number, etc., to justify the change, or in very simple changes, the actual data on the CR / CO. The CO needs to have a block referencing a check for need to file a new 510(k) per two FDA Guidance Documents on changes to a device requiring a new 510(k) (replacing the old Memorandum K97-1), and also tied to some kind of list / log of changes for a cumulative change review as well per those same Guidances. All this is filed in Document Control, usually under QA (as would a closed out DHF, in many companies).
Of course this requires that document changes be defined in such a way in an SOP to allow device changes (which are usually driven by a document change anyway, e.g., drawing change, specification change, etc.). When there is fielded software (firmware or software) and a revised version is created under change control, how does this affect the DMR and / or DHR?
Any change to a product, hardware or software, requires
a change to the DMR (under change control, 820.40) for that product). Often the DMR includes a DHR template / blank (may be a "traveler" template / blank, or in addition to a traveler), which would also be changed, or would at least drive a change to the DHR anyway, reflecting the new Revision / Release numbers of the software so changed (unless the Revision / Release Number entry is a fill-in blank).
“Travelers” often address and document actual equipment settings (as opposed to ranges established by validation and outlined in SOPs, etc.), line clearance verification / sign-off, label count reconciliations, filled in BOMs (with lot numbers and quantity), inspection results and sign-offs by QC, non-conformance resolutions and approvals, deviations / completion / verification and approval, et al, and a final DHR / lot review and sign-off by QA.
Consider the situation where a company has updated software that is then sent out to their customers. In such a case, one possibility is that both (DMR and DHR) are updated (the DMR drives DHR content), assuming that the software is changed across the board. If you're changing software for one customer at a time, then you're furnishing custom software, each program unique to each customer, and your entire CGMP system would have to be designed under that system. My discussion is focused on the assumption that the software is a revision / release, where all customers for that particular software get the same updates, new changes / revisions / releases. Of course, all changes (custom or generic) are done under change control.
To clarify the role of the DHF, DMR and DHR: The DHF shows the development of the device proving that the eight* other requirements of 820.30 Design Control or of ISO 13485 7.3, Design and Development Planning, have been met in its development from the "start" date (usually when serious money is committed by the company to commercialize a previous R&D research project).
The DMR is one result or design output from the DHF documented activities. The DMR (820.81) is the device description, or "recipe": basically a list of all controlled records ("living documents") that define the device, to allow it's replication as defined in the FDA clearance (510(k)) or approval (PMA) documents.
The DMR might list device drawings, assembly work instructions / SOPs, test instructions / SOPs, BOM blanks (part numbers and part / component descriptions with blanks for quantity and lot numbers), blank travelers (which may list applicable validated / verified equipment settings with blanks to be filled in with the actual settings, operator or QC signatures and dates, and similar), reference other device specific SOPs, labels, Instructions for Use. Some DMRs may list the generic SOPs that also apply to that device (and other devices), but don't have to. It would include the DHR template if additional to the above, e.g., traveler.
Additional on the DMR (the device "recipe"): Although riskier, you could structure the DMR to list the device controlling documents without their current revision nos. / dates (e.g., list Drawing No. 0123, "current revision"; or SOP XYZ, "current revision” ). Then the DMR would not
always have to be updated when the device or software has minor changes, or even some major changes. However, the actual DHR template would have to be updated to reflect using the most current documents / settings / parts , et al, during manufacture of a lot. All such changes would be under Change Control per 820.40.
The DHR (820.184) is the lot build history for one production lot; a record of how one lot / batch (lot number), or one serial number was built, quantities, RM lot numbers, dates, personnel involved where appropriate, proving that lot followed the "recipe" outlined in the DMR. It would have the filled in / signed BOM, a filled / signed traveler (which could be a "DHR template blank"), samples of labels / IFUs included, sterile lot info (if sterilized), etc., showing / proving conformance to the DMR developed by the manufacturing process recorded in the DHF. Prior to release of that lot to the field, it would be reviewed and signed by QA, who would assure its accuracy and completeness of data and required enclosed documents.
In essence: -- the DHF > DMR > DHRs. See also "Definitions", 820.3. These terms will change with the new US QMSR (new 21 CFR 820, which includes ISO 13485 and ISO 9000, Clause 3, by reference) replacing the old US QSR (old 21 CFR 820).
Technical Documentation / Files: This is a EU MDR term used to describe the documentation used to prove compliance to the EU MDR, especially the old MDD “Essential Requirements”, now referred to in the new MDR as the “General Safety and Performance Requirements”,
and the rest of the MDR and any applicable standards or other regulatory requirements for that family of devices. It’s closest comparison would be the US FDA’s 510(k), DeNovo, or PMA. Both are marketing authorizations, showing how the device meets its regulatory requirements in their respective countries and the vehicle to seek government regulatory clearance or approval for sale in those counties. Both are reviewed by either the US FDA, or a Certified Notified Body (outside the US), prior to receiving permission to market in their respective countries. The applicable manufacturing and quality / regulatory QMS is determined by the country(ies) where the device is to be marketed (no matter where manufactured).
The ultimate approach taken by a company must be defined by an SOP(s) and then followed!
*The 8 Design Control requirements:
-
Design and Development Planning (e.g., a Gantt Chart)
-
Design Input
-
Design Output
-
Design Review
-
Design Verification
-
Design Validation
-
Design Transfer
-
Design Changes
The remaining 2 elements of Design Control (total of 10):
-
Design Control SOP
-
Design History File (DHF)
John E. Lincoln
John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 40 years experience in U.S. FDA-regulated industries, 30 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, world wide. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide. John is a graduate of UCLA.
Watch Courses by John E. Lincoln
TalkFDA Affiliate Program — Terms & Conditions
1. Joining the Program
- By registering, you agree to these terms.
- Approval of applications is at TalkFDA’s sole discretion.
2. Affiliate Commissions
- Commission Rate: 20% of net sales (after refunds/discounts).
- Commission applies to initial purchase and recurring renewals.
- Payments are made monthly via [payment method] after a 30-day refund period.
3. Tracking & Attribution
- Tracking is done via unique Affiliate IDs.
- Last-click attribution is used (the most recent affiliate link gets credit).
- TalkFDA is not responsible for untracked sales caused by ad blockers, browser issues, or customer error.
4. Prohibited Practices
Affiliates must not:
- Use spam, fake accounts, bots, or misleading claims.
- Misrepresent TalkFDA’s services or guarantees.
- Bid on TalkFDA’s name, brand, or trademarks in paid search ads without prior permission.
- Self-refer (you can’t earn commission from your own purchases).
5. Promotion Guidelines
- Affiliates may promote via websites, blogs, social media, email lists (opt-in only).
- Promotion must be professional and respectful to TalkFDA’s reputation.
- Certain content (adult, hate speech, political, illegal) is strictly prohibited.
6. Termination
- TalkFDA reserves the right to suspend or terminate an affiliate account for any breach of these terms, or if the affiliate’s activity harms TalkFDA’s reputation.
- Any unpaid commissions may be forfeited if termination is due to violation of terms.
7. Liability
- Affiliates act as independent promoters and are not employees of TalkFDA.
- TalkFDA is not liable for indirect, special, or consequential damages related to the program.
8. Changes to the Program
- TalkFDA may update commission rates, terms, or program rules at any time.
- Affiliates will be notified of changes by email or via the Affiliate Dashboard.
9. Governing Law
- These terms are governed by the laws of Canada.
Credit Card required to activate Trial.
You won’t be charged unless you choose to continue after the trial period.
Welcome to TalkFDA Learning
Thank you for your purchase!
Some emails from TalkFDA may be filtered by company email systems.
- Please check the Inbox inside My Space (top right corner).
- Add @talkfda.com to your safe sender list.
Access & Support Information
-
Please check your Spam / Junk folder if you don’t receive emails shortly after purchase.
-
In some organizations, emails may be quarantined by IT security systems — you may need to contact your IT team.
-
We recommend adding @talkfda.com to your Safe Senders / Allow List.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Everything related to your webinar: access, materials, playback, and certification — lives in one place.

